



No: 2017/SEC/AUG/098

August 16, 2017

National Stock Exchange of India Limited
"Exchange Plaza", 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex
Bandra (East), Mumbai – 400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

NSE - Symbol - BIOCON

BSE - Scrip code - 532523

Dear Sir,

Sub: Company Statement on Status of EMA Dossiers.

Please find below the Company's statement on the subject matter.


- As previously communicated, whilst our drug substance facilities for Trastuzumab and Pegfilgrastim were approved, the European regulatory authorities had informed us of the need for a re-inspection of our drug product facility for these products.
- The request for withdrawal of the dossiers and re-submission is part of the EMA procedural requirements linked to this re-inspection and will be considered by the EMA's Committee for Medicinal Products for Human Use (CHMP).
- We are on track to complete our corrective and preventive actions (CAPAs) by the end of this quarter and it is our intent to seek re-inspection and re-submission thereafter.

-Company Spokesperson

Kindly take on record the same.

Thanking You,

Yours faithfully,
For **BIOCON LIMITED**


Rajiv Balakrishnan
Company Secretary

